Lomefloxacin HCl
产品说明书
 |
同义名 : | SC47111A hydrochloride; Lomefloxacin (hydrochloride); SC-47111; Lomefloxacin hydrochloride |
| CAS号 : | 98079-52-8 | |
| 货号 : | A215886 | |
| 分子式 : | C17H20ClF2N3O3 | |
| 纯度 : | 95% | |
| 分子量 : | 387.81 | |
| MDL号 : | MFCD00214312 | |
| 存储条件： |
Pure form Keep in dark place,Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
H2O: 7 mg/mL(18.05 mM)，配合低频超声，并水浴加热至45℃助溶 |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Lomefloxacin Hydrochloride is a useful broad spectrum antibacterial drug for a wide variety of clinical infections[3]. Microbiological studies showed 35 folds increase in the antibacterial activity of LF (Lomefloxacin Hydrochloride) niosomes compared to free drug; where MBC decreased from 31. 25 mcg/mL in case of LF solution to 0. 97 mcg/mL for niosomal gel[4]. Lomefloxacin decreases the cell viability in a dose- and time-dependent manner. For COLO829 cells treated with the drug for 24, 48, and 72 h, the values of IC50 were 0.51, 0.33, and 0.25 mM, respectively[5]. The antibacterial activity of P-LXN 7 evaluated using the susceptibility test and topical therapy of induced ocular conjunctivitis confirmed the enhanced antibacterial therapeutic efficacy of the LXN-proniosomal gel compared to the commercially available LXN (Lomefloxacin Hydrochloride) eye drops[6]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT02099240 | Osteomyelitis | Early Phase 1 | Recruiting | September 2019 | United States, Kentucky ... 展开 >> University of Louisville Recruiting Louisville, Kentucky, United States, 40202 Contact: Julio A Ramirez, MD 502-852-1148 jarami01@louisville.edu Contact: David Seligson, MD 502-852-0923 d0seli01@louisville.edu Sub-Investigator: Forest Arnold, DO Sub-Investigator: Timothy Wiemkwn, PhD Sub-Investigator: Robert Kelley, PhD Sub-Investigator: James Summersgill, PhD Sub-Investigator: Ruth Carrico, PhD Sub-Investigator: Julie Harting, PharmD Sub-Investigator: Paula Peyrani, MD Principal Investigator: David Seligson, MD Sub-Investigator: Craig Roberts, MD Principal Investigator: Julio Ramirez, MD 收起 << |
| NCT00258102 | Urinary Tract Infections ... 展开 >> Bacterial Infections Bacteriuria Urologic Diseases 收起 << | Phase 3 | Completed | - | - |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.58mL 0.52mL 0.26mL |
12.89mL 2.58mL 1.29mL |
25.79mL 5.16mL 2.58mL |
| 参考文献 |
|---|
|
[1]Al-Wabli RI. Lomefloxacin. Profiles Drug Subst Excip Relat Methodol. 2017;42:193-240. |